Not exact matches
(18) FDG PET / CT AFTER INTENSIFIED
CHEMO -
IMMUNOTHERAPY IN DIFFUSE LARGE B - CELL LYMPHOMA (DLBCL), AGED 18 - 65 YEARS
WITH AAIPI 2 - 3.
The FDA granted approval to durvalumab (IMFINZI ®, AstraZeneca), a checkpoint
immunotherapy that targets the PD - 1 / PD - L1 pathway, for patients
with unresectable, stage III non-small cell lung cancer (NSCLC) that hasn't progressed after prior
chemo - radiation treatment.
Researchers are investigating nanoparticles for delivery of immunostimulatory or immunomodulatory molecules in combination
with chemo - or radiotherapy or as adjuvants to other
immunotherapies.
With chemo and / or immunotherapy, dogs with only Stage 1 or Stage 2 of the disease may live several months up to one year after treatm
With chemo and / or
immunotherapy, dogs
with only Stage 1 or Stage 2 of the disease may live several months up to one year after treatm
with only Stage 1 or Stage 2 of the disease may live several months up to one year after treatment.